Knowledge Base - Massachusetts Biotechnology Council - Massachusetts Biotechnology Council

Hogan Lovells: Life Sciences and Health Care Horizons 2019 Hogan Lovells March 22, 2019

In the 2019 edition of our Life Sciences and Health Care Horizons publication, our global team identifies a number of current and evolving trends that are shaping the future of the industry. Read More

Pricing for Survival: As demand for pharmaceutical cost containment intensifies, novel drug-pricing approaches are critical KPMG LLP April 19, 2018 in White Papers,

Drug Cost,
Value

In this piece, we explore the practical approaches to pricing for value that pharma manufacturers can leverage today. Read More

Life Sciences and Health Care Horizons 2018 Hogan Lovells March 28, 2018 in White Papers,

Our global Life Sciences and Health Care team reports on current and evolving trends that are shaping the future of the industry. Read More

Business success in the life sciences: an investment banker’s perspective June 28, 2017 in White Papers,

As we are passionate about bringing paradigm-shifting technologies to patients, we were excited by the opportunity to facilitate transatlantic collaborations between Boston’s biotech hub and the life Read More

Platforms versus products in the life sciences sector June 23, 2017

In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital Read More

Automating Excursion Management for Real-Time Resolution in the Pharmaceutical Manufacturing Process New England Controls November 29, 2016 in White Papers,

This paper summarizes traditional methods of tracking excursions and presents an alternative automated method to track and resolve excursions in a more timely fashion that will reduce the time and costs associated with... Read More

Ensure Productivity, Compliance, and Quality with Emerson's Syncade MES New England Controls November 29, 2016 in White Papers,

With Syncade, Repligen has much better control of documents and revisions. Industry practice requires biannual review of controlled documents. The old system did not enforce this practice because the entire remind-and-review... Read More

Direct-to-Patient Shipping Toolkit July 21, 2016 in White Papers,

Wondering what the new direct-to-patient shipping innovation is and how you next study could benefit? Read More

Testimony of Robert K. Coughlin President & CEO, MassBio at Joint Committee on Healthcare Financing April 11, 2016 April 13, 2016 in White Papers,